Data highlights preclinical efficacy and safety of GNX1021, a novel glycan-targeting ADC, in gastric cancer models NEW TAIPEI CITY, Taiwan, March 27, 2025 /PRNewswire/ -- GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the...
Hence then, the article about glyconex to present preclinical data on gnx1021 at aacr 2025 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( GlycoNex to Present Preclinical Data on GNX1021 at AACR 2025 )
Also on site :
- OpenAI buys tiny health records startup Torch for, reportedly, $100M
- Meta-backed Hupo finds growth after pivot to AI sales coaching from mental wellness
- TCL Dominates CES 2026 with Ultimate Display Innovation